Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder

February 8, 2021 updated by: Margaret McKinnon, St. Joseph's Healthcare Hamilton

Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders

Individuals with affective disorders (including post-traumatic stress disorder (PTSD) and major depressive disorder (MDD)) often experience declines in cognitive abilities such as memory and attention. Such difficulties can reduce functioning in important aspects of life, including at work or school. Little research has been conducted to investigate if cognitive dysfunction can be reduced in individuals with PTSD or MDD following a specific treatment. Thus, the investigators plan to determine the utility of a cognitive training program called goal management training (GMT) in reducing cognitive dysfunction in MDD/PTSD. GMT aims to assist participants in building skills in performing specific behaviours that rely on basic cognitive processes, allowing them to achieve an identified goal. 64 individuals with PTSD and 64 with MDD will be divided into two groups of 32, one GMT group, and one wait-list group that will receive GMT after study completion. The investigators predict that in comparison to the wait-list group, the GMT group will show greater improvements in cognitive functioning and everyday functioning following treatment and that these improvements will remain long-term.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In addition to their core affective components, MDD and PTSD are associated with poor cognitive functioning across a host of highly similar domains, including declarative memory, short-term memory, attention, and executive functioning. These deficits have been associated with reduced response to pharmacological and non-pharmacological interventions and poor functional outcomes. Given the potentially devastating impact of poor cognitive functioning on the ability of patients with affective disorders to benefit from treatment interventions, and its association with poor functional outcomes, there is an urgent need to identify novel treatment interventions aimed at reducing cognitive dysfunction in these disorders. Accordingly, the aim of the present proposal is to a randomized controlled trial examining the efficacy of a well-established cognitive intervention aimed at reducing attentional and executive dysfunction, Goal Management Training® (GMT), in the treatment of cognitive deficits among patients with MDD and with PTSD. A secondary aim is to determine the longer-term impact of this approach on functional outcomes.

Importantly, limited investigation of cognitive remediation therapy has been performed in these populations. Only one study has been conducted to examine the impact of a non-standardized intervention protocol aimed at improving cognitive functioning in PTSD. Here, clinically (but not statistically) significant improvements were noted in a small pilot study on measures of cognitive functioning after employing bottom-up executive training approach in conjunction with transcranial direct current sample of four patients. Previously, the investigators have applied computer-assisted cognitive remediation, a bottom-up restitution based approach, in patients with MDD, resulting in improvements in performance on working memory tasks in conjunction with increased functional activity in lateral prefrontal and parietal areas, however, the broad benefits of this training observed in a small sample (n=12) did not generalize to a larger group.

GMT has demonstrated efficacy in several clinical and non-clinical populations that experience deficits in executive functioning, attention, and memory (similar to those seen in MDD and PTSD), including older adults, individuals who have suffered a traumatic brain injury, have attention-deficit hyperactivity disorder (ADHD), poly-substance abuse disorder, or spina bifida. In these studies, participants showed improvements in completing every-day tasks (as measured by self-report), as well as improvements in executive functions such as decision-making, working memory and selective attention. Critically, these results were maintained at follow-up (when assessed). Given the previous success of this intervention in remediating frontal-temporally mediated brain dysfunction across clinical populations, the investigators hypothesize that GMT has the ability to target similar cognitive difficulties experienced by those suffering from MDD and from PTSD. The investigators will further examine whether putative improvements in cognitive performance will translate to functional improvements analogous to those seen in other psychiatric populations undergoing cognitive remediation.

In the current study, the investigators will conduct the first study to investigate the utility of GMT in patients with MDD or with PTSD. Specifically, the primary aim of this proposed study is to examine whether a standardized 9-week program of GMT results in durable improvements in cognitive functioning relative to a wait-list control (WLC). A secondary aim will be to determine whether participation in the GMT group is associated with long-term functional improvements. The investigators hypothesize that at post-treatment, participants with MDD and with PTSD assigned to the GMT groups will show significantly greater improvement in neuropsychological test performance and greater functional improvement compared to participants in the WLC group; these gains are expected to be maintained at 3 month follow-up.

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Hamilton, Ontario, Canada, L8N3K7
        • St. Joseph's Healthcare Hamilton

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Structured Clinical Interview for DSM-IV-TR for Axis I Disorders (SCID-I (First et al., 1996))-confirmed primary diagnosis of MDD or PTSD
  2. between the age of 18-60
  3. able to provide written informed consent.

Exclusion Criteria:

  1. Receiving treatment with anti-cholinergic or anti-psychotic medication
  2. have had electroconvulsive therapy within the past year
  3. a history of substance dependence or significant and recent (< 1 year) substance abuse)
  4. a recent history (within the past 12 months) of medical disorder known to adversely affect cognition
  5. loss of consciousness greater than 1 minute or a history of traumatic brain injury

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Goal Management Training
Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
Behavioral: Goal Management Training
Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
No Intervention: Wait List Control
Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Verbal and Phonemic Fluency on the Controlled Oral Word Association Task
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Processing speed and response inhibition on the Stoop Colour and Word Test
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Attention alternation on the Trail Making Test Part B
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Forming and shifting concepts on the Wisconsin Card Sorting Task
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Processing speed on the Weschler Adult Intelligence Scale IV - Symbol Coding subtest
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Inattentiveness, impulsivity, sustained attention and vigilance on Connors Continuous Performance Task
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Working memory on the N-back Task
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Measures ability to maintain and manipulate auditory information in memory.
Change from baseline to 9 week and 3 month follow-ups.
Immediate and delayed memory, interference learning and recognition on the California Verbal Learning Test II
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Contextually based memory on the Weschler Memory Scale III - Logical Memory
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Nonverbal visuospatial memory on the Brief Visuospatial Memory Test - Revised
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Current intellectual functioning on the Weschler Abbreviated Scale of Intelligence - II
Time Frame: Baseline
Baseline
Pre-morbid intellectual functioning on the National Adult Reading Test
Time Frame: Baseline
Baseline
Self-reported executive difficulties on the Dysexecutive Questionnaire
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Self reported daily errors in distractibility, blunders, and memory on the Cognitive Failures Questionnaire
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Self reported work, education, and residential functioning on the Multidimensional Scale of Independent Functioning
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Disability in work, social relationships, and family life on the Sheehan Disability Scale
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Functional competence on the Canadian Objective Assessment of Life Skills - Brief Version
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.

Secondary Outcome Measures

Outcome Measure
Time Frame
Current PTSD symptomatology on the Clinician Administered PTSD Scale for DSM 5
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Exposure ot childhood trauma on the Childhood Trauma Questionnaire
Time Frame: Baseline
Baseline
Dissociative symptoms on the Multiscale Dissociation Inventory
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Current depressive symptomatology on the Beck Depression Inventory - II
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.
Current anxiety symptomatology on the Beck Anxiety Inventory
Time Frame: Change from baseline to 9 week and 3 month follow-ups.
Change from baseline to 9 week and 3 month follow-ups.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Psychiatric diagnosis on the Structured Clinical Interview for DSM-IV - Text Revision
Time Frame: Baseline
Assesses axis I disorders from the DSM-IV.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Joseph's Healthcare Hamilton

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Actual)

August 1, 2018

Study Completion (Actual)

August 1, 2018

Study Registration Dates

First Submitted

July 15, 2015

First Submitted That Met QC Criteria

July 16, 2015

First Posted (Estimate)

July 20, 2015

Study Record Updates

Last Update Posted (Actual)

February 11, 2021

Last Update Submitted That Met QC Criteria

February 8, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0416

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on Goal Management Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe